Fosun Pharma: Neoplasms trials

The registry lists 19 Neoplasms studies with Fosun Pharma as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 16Phase 2 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 MutationNot yet recruitingNCT05528406Phase 2
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid TumorsNot yet recruitingNCT05442996Phase 1
• HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid TumorsRecruitingNCT04965220Phase 1
• A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard TherapyRecruitingNCT03941574Phase 2
• Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and PharmacokineticsActive, not recruitingNCT06980454Phase 1
• FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsActive, not recruitingNCT06858618Phase 2
• A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05483530Phase 1
• Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid TumorCompletedNCT05400265Phase 1
• A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid TumorsActive, not recruitingNCT05394168Phase 1
• A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or LymphomaStatus unknownNCT05390528Phase 1/2
• HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid TumorsStatus unknownNCT05360368Phase 1
• Study of FCN-098 in Patients With Advanced Solid TumorStatus unknownNCT05212987Phase 1
• A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid TumorWithdrawnNCT04797468Phase 1
• Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）Status unknownNCT04687423Phase 1
• Study of FCN-437c in Patients With Advanced Solid TumorsCompletedNCT03951116Phase 1
• Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2CompletedNCT03916094Phase 1
• A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsStatus unknownNCT03757936Phase 1
• A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid TumorsCompletedNCT03588650Phase 1
• The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.CompletedNCT03577704Phase 1/2